Sermorelin

Description

Sermorelin Reference Material | GHRH(1-29) Fragment

Sermorelin (GHRH 1-29 NH2; MW 3,357.93 g/mol) is a synthetic peptide comprising the first 29 amino acids of endogenous growth hormone-releasing hormone — the minimal fragment retaining full GHRH receptor binding and somatotroph activation activity. It was the first GHRH analog to receive FDA approval (pediatric GH deficiency) and provides researchers with a well-characterized, shorter-half-life GHRH reference ligand.

Pharmacological Context

Sermorelin’s half-life of approximately 10–20 minutes in preclinical models produces acute, pulsatile GH secretion patterns that closely mirror endogenous GHRH physiology. This makes it the reference compound of choice for studies requiring preserved GH pulsatility, in contrast to longer-acting GHRH analogs (CJC-1295, Tesamorelin) that produce sustained GH elevation with attenuated pulsatility.

Laboratory Research Applications

• GHRH receptor pharmacology — minimal active fragment studies
• Acute somatotroph GH pulse research
• GH pulsatility pattern studies under GHRH receptor activation
• Comparative GHRH fragment potency and duration studies
• GH/IGF-1 axis feedback loop research

Specifications

• Molecular Weight: 3,357.93 g/mol
• Form: Lyophilized powder
• Purity: ≥98% (HPLC verified)
• Storage: 2–8°C; -20°C long-term

For laboratory research use only. Not for human or veterinary use.